https://www.pharmaceutical-technology.com/analyst-comment/health-risks-upfs-worse-than-thought/ 2024-02-29T16:15:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/cdmo-indenas-long-term-vision/ 2024-02-29T15:28:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/obesity-cost-us-businesses-425-5bn-in-2023/ 2024-02-29T15:25:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/indenas-cdmo-services-health-is-a-joint-project/ 2024-02-29T15:06:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/shifting-the-paradigm-novel-approaches-to-amyotrophic-lateral-sclerosis-therapy/ 2024-02-29T13:53:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tata-institute-tablet-cancer-recurrence/ 2024-02-29T10:58:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/every-cure-grant-drug-repurposing/ 2024-02-29T11:02:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nhs-belumosudil-chronic-gvhd/ 2024-02-29T08:32:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-streamlines-approval-process/ 2024-02-29T08:19:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotechs-heed-political-headwinds-for-drug-pricing-negotiations-and-partnerships/ 2024-02-28T20:12:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotech-execs-say-ira-is-causing-unintended-effects-for-cancer-drug-development/ 2024-02-28T20:07:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/beyond-approval-patients-pursue-alternate-paths-to-get-rare-disease-treatments/ 2024-05-02T15:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-and-fda-green-light-moonlake-to-advance-il-17-inhibitor/ 2024-02-28T17:12:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-licenses-oses-chronic-inflammation-therapy-for-48m-upfront/ 2024-02-28T16:24:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/biogen-discontinues-aduhelm-alzheimers/ 2024-02-28T16:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/beacon-therapeutics-gene-therapy-agtc-501/ 2024-02-28T15:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-importance-of-high-quality-raw-materials-in-the-development-of-regenerative-medicine/ 2024-02-28T15:33:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/minerva-hit-with-fda-rejection-for-schizophrenia-symptom-drug/ 2024-02-28T11:35:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/grifols-prepares-for-late-stage-plans-with-plasma-derived-medicines-in-2024/ 2024-06-17T14:05:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/beigene-tevimbra-gastric-cancer/ 2024-02-28T10:49:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pelage-funds-hair-loss/ 2024-02-28T10:41:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/amneal-zambon-parkinsons-therapy/ 2024-02-28T09:37:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-allecra-exblifep/ 2024-02-28T09:37:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/operational-risks-with-gene-therapies-should-improve-with-time-exec-says/ 2024-02-27T22:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/innovation-takes-precedence-with-ai-use-for-techbios-in-pharma/ 2024-02-27T22:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringers-obesity-drug-shows-efficacy-for-liver-disease/ 2024-02-27T17:46:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-signs-1-46bn-deal-to-develop-molecular-glue-therapies/ 2024-02-27T15:16:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/telix-footprint-isotherapeutics-acquisition/ 2024-02-27T10:05:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-biktarvy-fda-approval/ 2024-02-27T10:35:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-rayzebio/ 2024-02-27T09:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-chmp-astrazeneca-voydeya/ 2024-02-27T08:04:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/2seventy-bio-patent-activity/ 2024-07-21T17:14:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/quidelortho-patent-activity/ 2024-07-21T17:14:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dyne-therapeutics-patent-activity/ 2024-07-21T17:14:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aligos-therapeutics-patent-activity/ 2024-07-21T17:14:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jacobio-pharmaceuticals-group-patent-activity/ 2024-07-21T17:14:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/beam-therapeutics-patent-activity/ 2024-07-21T17:14:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krystal-biotech-patent-activity/ 2024-02-27T06:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arcutis-biotherapeutics-patent-activity/ 2024-07-21T17:14:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/praxis-precision-medicines-patent-activity/ 2024-07-21T17:13:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vir-biotechnology-patent-activity/ 2024-07-21T17:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xbiotech-patent-activity/ 2024-02-27T06:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/genertec-universal-medical-group-patent-activity/ 2024-02-27T06:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carsgen-therapeutics-patent-activity/ 2024-07-21T17:13:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/c4-therapeutics-patent-activity/ 2024-07-21T17:13:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzychem-lifesciences-patent-activity/ 2024-07-21T17:13:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alkermes-patent-activity/ 2024-07-21T17:13:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sihuan-pharmaceutical-holdings-group-patent-activity/ 2024-07-21T17:13:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viking-therapeutics-patent-activity/ 2024-07-21T17:13:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shilpa-medicare-patent-activity/ 2024-09-16T07:38:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/protagonist-therapeutics-patent-activity/ 2024-07-21T17:13:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neurocrine-biosciences-patent-activity/ 2024-07-21T17:13:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jubilant-pharmova-patent-activity/ 2024-07-21T17:13:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bukwang-pharmaceutical-patent-activity/ 2024-07-21T17:13:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/novavax-patent-activity/ 2024-07-21T17:13:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocular-therapeutix-patent-activity/ 2024-07-21T17:13:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bioatla-patent-activity/ 2024-07-21T17:13:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogaia-patent-activity/ 2024-07-21T17:13:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mersana-therapeutics-patent-activity/ 2024-07-21T17:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glenmark-pharmaceuticals-patent-activity/ 2024-07-21T17:13:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zeria-pharmaceutical-patent-activity/ 2024-07-21T17:13:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medartis-patent-activity/ 2024-07-21T17:13:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/samsung-biologics-patent-activity/ 2024-07-21T17:13:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ngm-biopharmaceuticals-patent-activity/ 2024-07-21T17:13:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/argenx-patent-activity/ 2024-07-21T17:13:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/compugen-patent-activity/ 2024-07-21T17:12:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zymeworks-patent-activity/ 2024-07-21T17:12:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omeros-patent-activity/ 2024-07-21T17:12:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anavex-life-sciences-patent-activity/ 2024-07-21T17:12:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/porton-pharma-solutions-patent-activity/ 2024-07-21T17:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/galapagos-patent-activity/ 2024-07-21T17:12:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deciphera-pharmaceuticals-patent-activity/ 2024-02-27T05:56:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caribou-biosciences-patent-activity/ 2024-07-21T17:12:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hu-group-patent-activity/ 2024-07-21T17:12:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/charles-river-laboratories-international-patent-activity/ 2024-07-21T17:12:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allakos-patent-activity/ 2024-07-21T17:12:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-science-patent-activity/ 2024-07-21T17:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anaptysbio-patent-activity/ 2024-07-21T17:12:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anges-patent-activity/ 2024-07-21T17:12:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellectis-patent-activity/ 2024-07-21T17:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merus-patent-activity/ 2024-07-21T17:12:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biomarin-pharmaceutical-patent-activity/ 2024-07-21T17:12:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axsome-therapeutics-patent-activity/ 2024-07-21T17:12:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/3sbio-patent-activity/ 2024-07-21T17:12:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cha-biotech-patent-activity/ 2024-07-21T17:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precision-biosciences-patent-activity/ 2024-07-21T17:12:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hanall-biopharma-patent-activity/ 2024-02-27T05:52:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oxford-biomedica-patent-activity/ 2024-02-27T05:52:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovent-biologics-patent-activity/ 2024-07-21T17:12:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-pharma-patent-activity/ 2024-07-21T17:12:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurinia-pharmaceuticals-patent-activity/ 2024-07-21T17:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/akeso-patent-activity/ 2024-07-21T17:12:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cytokinetics-patent-activity/ 2024-07-21T17:11:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biocon-patent-activity/ 2024-07-21T17:11:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/endo-international-patent-activity/ 2024-07-21T17:11:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jw-patent-activity/ 2024-07-21T17:10:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/athenex-patent-activity/ 2024-07-21T17:10:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aska-pharmaceutical-patent-activity/ 2024-02-27T05:49:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wave-life-sciences-patent-activity/ 2024-07-21T17:08:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tcr2-therapeutics-patent-activity/ 2024-02-27T05:49:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adverum-biotechnologies-patent-activity/ 2024-07-21T17:10:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cytomx-therapeutics-patent-activity/ 2024-07-21T17:06:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncopeptides-patent-activity/ 2024-07-21T17:07:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ardelyx-patent-activity/ 2024-07-21T17:07:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shanghai-haohai-biological-technology-patent-activity/ 2024-05-30T01:00:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bayer-wins-fda-breakthrough-therapy-designation-for-nsclc-candidate/ 2024-02-26T15:56:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-clears-pk-med-to-streamline-gout-injectable-to-phase-ii/ 2024-02-26T15:03:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-receives-ema-chmp-recommendation-for-als-drug-qalsody/ 2024-02-26T14:09:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/streamlining-supply-chain-operations-in-focus-at-clinical-trial-supply-europe-2024/ 2024-02-27T16:49:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-keytruda-ema-chmp/ 2024-02-26T11:00:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sk-bioscience-typhoid-vaccine-who-prequalification/ 2024-02-26T10:10:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-mrna-vaccine-facility-canada/ 2024-05-30T08:02:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alvotech-tevas-simlandi-injection/ 2024-02-26T09:14:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-generic-drug-approvals-rose-in-2023-in-bid-for-improved-access/ 2024-02-23T16:15:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chmp-provides-positive-opinion-for-bmss-reblozyl/ 2024-02-23T15:44:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-to-decide-on-sanofi-regenerons-dupixent-for-copd-in-june/ 2024-02-23T15:12:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/anticipation-rises-for-rsv-rollout-as-positive-data-emerges/ 2024-04-03T12:20:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bavarian-nordics-chikungunya-vaccine-secures-ema-fast-track/ 2024-02-23T12:36:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-net-loss-full-year-2023/ 2024-02-23T10:39:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/nice-recommends-pfizer-ritlecitinib/ 2024-02-23T10:48:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/five-years-of-firstline-in-the-united-states/ 2024-02-28T16:44:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-completes-gracell-acquisition/ 2024-02-23T09:25:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-tentarix-biologic-deal/ 2024-02-23T09:25:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/digital-transformation-of-the-supply-chain-will-make-data-more-valuable-are-you-prepared/ 2024-04-23T12:01:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunocore-and-bms-partner-to-investigate-first-line-treatment-for-melanoma/ 2024-02-22T16:56:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/harmony-wins-orphan-drug-tag-for-pitolisant-to-treat-prader-willi-syndrome/ 2024-02-27T17:52:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immune-oncs-antibody-therapy-collects-second-fda-orphan-designation/ 2024-02-22T15:51:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/united-therapeutics-sues-fda-over-handling-of-liquidias-nda/ 2024-02-22T15:32:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-revokes-authorisation-novartis-adakveo/ 2024-02-22T11:00:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ono-pharmaceutical-partners-eme/ 2024-02-22T10:59:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/telehealth-abortion-is-an-effective-safe-tool-for-equitable-healthcare-us-study/ 2024-02-22T10:48:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/charles-river-wheeler-therapeutic-discovery/ 2024-02-22T09:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-regeneron-bla-linvoseltamab/ 2024-02-22T09:21:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apilimod-mesylate-orphai-therapeutics-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-02-22T00:25:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-lupin-post-menopausal-osteoporosis-likelihood-of-approval/ 2024-02-22T00:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/23me610-23andme-holding-merkel-cell-carcinoma-likelihood-of-approval/ 2024-04-19T17:10:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/23me610-23andme-holding-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-02-22T00:15:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sarilumab-regeneron-pharmaceuticals-polyarticular-juvenile-idiopathic-arthritis-pjia-likelihood-of-approval/ 2024-02-22T00:05:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/squaric-acid-dibutyl-ester-squarex-pharmaceutical-herpes-labialis-oral-herpes-likelihood-of-approval/ 2024-02-21T23:47:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-filament-health-treatment-resistant-depression-likelihood-of-approval/ 2025-01-19T18:06:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seagen-gets-grant-for-cancer-drug-conjugates-targeting-mdr-cells-with-bystander-activity/ 2024-04-17T12:02:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascendis-pharma-gets-grant-for-il-2-protein-conjugates-for-cancer-treatment/ 2024-04-17T11:59:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bicycle-therapeutics-gets-grant-for-high-affinity-peptide-binders-for-thymic-stromal-lymphopoietin-tslp/ 2024-04-15T12:50:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rigel-pharmaceuticals-gets-grant-for-treatment-of-conditions-by-compounds-of-formula-iv/ 2024-04-15T12:54:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/les-laboratoires-servier-gets-grant-for-medicament-manufacturing-using-compound-of-formula-i/ 2024-04-15T12:48:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ac-immune-gets-grant-for-novel-compounds-for-treating-tau-protein-related-disorders/ 2024-04-15T12:43:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/johnson-johnson-gets-grant-for-minimally-invasive-access-device-for-intervertebral-disc-surgery/ 2024-04-15T12:47:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grupo-ferrer-internacional-gets-grant-for-electric-heating-unit-without-igniter-using-metal-oxidation-reduction-reaction/ 2024-04-15T12:26:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hisamitsu-pharmaceutical-gets-grant-for-osteoarthritis-treatment-patch-with-specific-adhesive-and-diclofenac-dosage/ 2024-04-15T12:32:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pepgen-earns-fda-fast-track-designation-for-myotonic-dystrophy-type-1-candidate/ 2024-02-21T16:39:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-bans-otc-sale-of-codeine-after-recreational-abuse-reports/ 2024-02-21T16:38:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bavarian-nordics-revenue-soars-post-mpox-outbreaks/ 2024-02-21T16:32:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/smart-tech-ulcerative-colitis/ 2024-02-21T13:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/polpharma-looks-to-challenge-takedas-entyvio-in-ibd/ 2024-07-08T14:48:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genezen-licence-csl-system/ 2024-02-21T11:17:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/wuxi-amtagvi-manufacturing-site/ 2024-02-21T10:22:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-krazati-snda-priority-review/ 2024-02-21T09:13:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-jj-multiple-myeloma-treatment/ 2024-02-21T09:16:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07872412-pfizer-streptococcal-pneumonia-likelihood-of-approval/ 2025-01-21T16:51:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ketamine-nrx-pharmaceuticals-bipolar-disorder-manic-depression-likelihood-of-approval/ 2025-01-21T16:51:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-921-biomed-industries-fragile-x-syndrome-likelihood-of-approval/ 2024-07-05T18:19:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-921-biomed-industries-rett-syndrome-likelihood-of-approval/ 2024-07-05T18:19:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/not-disclosed-neurodegeneration-eli-lilly-and-co-neurodegenerative-diseases-likelihood-of-approval/ 2024-02-20T19:26:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-442970-sanofi-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-21T16:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sy-001-cellorigin-technology-hangzhou-solid-tumor-likelihood-of-approval/ 2025-01-21T16:50:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rioderm-001-rion-diabetic-foot-ulcers-likelihood-of-approval/ 2024-05-20T05:25:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rioderm-003-rion-radiodermatitis-likelihood-of-approval/ 2024-02-20T19:25:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rm-191a-rr-medsciences-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-02-20T19:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/l-and-j-hz-l-j-bio-herpes-zoster-shingles-likelihood-of-approval/ 2024-02-20T19:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amikacin-pureims-tuberculosis-likelihood-of-approval/ 2024-03-19T01:53:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9829-astrazeneca-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T15:58:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-604-novartis-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T16:50:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-11-cellebrain-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-02-20T19:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-141-abbvie-fibrosis-likelihood-of-approval/ 2024-02-20T19:22:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9829-astrazeneca-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-19T15:58:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9829-astrazeneca-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T15:58:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-446422-sanofi-inflammation-likelihood-of-approval/ 2025-01-21T16:50:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07899895-pfizer-ulcerative-colitis-likelihood-of-approval/ 2024-02-20T19:22:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neuroncell-ex-cytopeutics-acute-ischemic-stroke-likelihood-of-approval/ 2024-02-20T19:21:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-3470-astrazeneca-solid-tumor-likelihood-of-approval/ 2024-09-09T05:51:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hodo-2224-hyundai-pharma-cardiovascular-disease-likelihood-of-approval/ 2025-01-21T16:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046045-pfizer-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:50:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046045-pfizer-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-21T16:50:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046045-pfizer-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T16:50:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046045-pfizer-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T16:50:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046045-pfizer-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gim-122-georgiamune-solid-tumor-likelihood-of-approval/ 2024-04-20T04:41:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-bio-thera-solutions-solid-tumor-likelihood-of-approval/ 2025-01-21T16:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kb-707-krystal-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T16:50:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07868489-pfizer-pulmonary-arterial-hypertension-likelihood-of-approval/ 2024-02-20T19:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-hematological-tumor-likelihood-of-approval/ 2024-09-09T05:51:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tgi-2-hefei-tg-immunopharma-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:51:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tgi-2-hefei-tg-immunopharma-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-09-09T05:51:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046050-pfizer-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T18:19:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tgi-2-hefei-tg-immunopharma-metastatic-melanoma-likelihood-of-approval/ 2024-09-09T05:51:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tgi-2-hefei-tg-immunopharma-solid-tumor-likelihood-of-approval/ 2024-09-09T05:51:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046050-pfizer-gastric-cancer-likelihood-of-approval/ 2024-07-05T18:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046050-pfizer-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:19:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046050-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:19:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danegaptide-breye-therapeutics-diabetic-retinopathy-likelihood-of-approval/ 2024-07-05T18:19:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danegaptide-breye-therapeutics-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-07-05T18:19:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tris-car-t-tasly-pharmaceutical-group-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-02-20T19:12:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tetralite-litevax-seasonal-influenza-likelihood-of-approval/ 2024-04-20T04:40:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/riboflavin-sodium-iodide-epion-therapeutics-keratoconus-likelihood-of-approval/ 2025-01-21T16:50:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/riomsk-001-rion-osteoarthritis-likelihood-of-approval/ 2025-01-21T16:50:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-325-duality-biologics-shanghai-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T16:50:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd70-car-t-cells-chongqing-precision-biotech-gynecological-cancer-likelihood-of-approval/ 2025-01-21T16:50:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-320-crispr-therapeutics-atherosclerosis-likelihood-of-approval/ 2025-01-21T16:50:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-20062-lg-chem-haemophilus-influenzae-type-b-infections-likelihood-of-approval/ 2025-01-21T16:50:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sion-109-sionna-therapeutics-cystic-fibrosis-likelihood-of-approval/ 2024-02-20T19:10:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-325-duality-biologics-shanghai-peritoneal-cancer-likelihood-of-approval/ 2025-01-21T16:50:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-20062-lg-chem-poliomyelitis-likelihood-of-approval/ 2025-01-21T16:49:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-20062-lg-chem-tetanus-likelihood-of-approval/ 2025-01-21T16:49:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-20062-lg-chem-diphtheria-likelihood-of-approval/ 2025-01-21T16:49:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mr-107a02-viatris-post-operative-pain-likelihood-of-approval/ 2025-01-21T16:49:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lr-20062-lg-chem-hepatitis-b-likelihood-of-approval/ 2025-01-21T16:49:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/absk-112-abbisko-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T16:49:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aga-2118-angitia-biopharmaceuticals-osteoporosis-likelihood-of-approval/ 2025-01-21T16:49:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/montelukast-sodium-jiangyin-berrysen-pharmaceutical-cervical-cancer-likelihood-of-approval/ 2025-01-21T16:49:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/montelukast-sodium-jiangyin-berrysen-pharmaceutical-radiation-injury-likelihood-of-approval/ 2025-01-21T16:49:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/montelukast-sodium-jiangyin-berrysen-pharmaceutical-endometrial-cancer-likelihood-of-approval/ 2025-01-21T16:49:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/askc-202-jiangsu-aosaikang-pharmaceutical-lung-cancer-likelihood-of-approval/ 2025-01-21T16:49:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-802-novartis-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T16:49:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dzd-8586-dizal-pharmaceutical-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T16:49:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-365598-viiv-healthcare-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-06-19T15:57:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dzd-8586-dizal-pharmaceutical-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T16:49:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/skp-0160-sk-plasma-hemostasis-likelihood-of-approval/ 2025-01-21T16:49:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sg-2501-hangzhou-sumgen-biotech-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:49:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sg-2501-hangzhou-sumgen-biotech-primary-systemic-amyloidosis-likelihood-of-approval/ 2025-01-21T16:49:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sg-2501-hangzhou-sumgen-biotech-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-21T16:49:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mt-110-myosin-therapeutics-substance-drug-abuse-likelihood-of-approval/ 2025-01-21T16:48:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sg-2501-hangzhou-sumgen-biotech-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T16:48:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sg-2501-hangzhou-sumgen-biotech-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T16:48:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spl-84-splisense-cystic-fibrosis-likelihood-of-approval/ 2025-01-21T16:48:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-zhuhai-beihai-biotech-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T16:48:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aclx-002-arcellx-myelodysplastic-syndrome-likelihood-of-approval/ 2024-02-20T18:57:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aclx-002-arcellx-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-02-20T18:57:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aclx-002-arcellx-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-02-20T18:57:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2024-09-09T05:51:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046052-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T16:48:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evo-756-evommune-chronic-urticaria-or-hives-likelihood-of-approval/ 2025-01-21T16:48:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046052-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T16:48:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046052-pfizer-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:48:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046052-pfizer-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T16:48:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glecirasib-jacobio-pharmaceuticals-group-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T16:48:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glecirasib-jacobio-pharmaceuticals-group-biliary-tumor-likelihood-of-approval/ 2025-01-21T16:48:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bh-3120-hanmi-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-04-20T04:39:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vg-3927-vigil-neuroscience-alzheimer-s-disease-likelihood-of-approval/ 2024-02-20T18:53:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0901-astrazeneca-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-09-09T05:51:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glecirasib-jacobio-pharmaceuticals-group-gastric-cancer-likelihood-of-approval/ 2025-01-21T16:48:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saruparib-astrazeneca-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-07-05T18:18:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-5462688-gsk-alpha-1-antitrypsin-deficiency-a1ad-likelihood-of-approval/ 2025-01-21T16:48:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saruparib-astrazeneca-metastatic-prostate-cancer-likelihood-of-approval/ 2024-07-05T18:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/saruparib-astrazeneca-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2024-07-05T18:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2618-chia-tai-tianqing-pharmaceutical-group-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T16:48:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-solid-tumor-likelihood-of-approval/ 2024-06-19T15:57:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dwp-708-daewoong-pharmaceutical-skin-rash-likelihood-of-approval/ 2024-02-20T18:49:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levoxiracetam-nanjing-yoko-biomedical-memory-impairment-likelihood-of-approval/ 2024-03-19T01:52:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/everest-ends-covid-19-mrna-vaccine-deal-with-providence/ 2024-05-30T08:02:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lutetium-miltuximab-glytherix-ureter-cancer-likelihood-of-approval/ 2024-05-20T05:23:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lutetium-miltuximab-glytherix-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-05-20T05:23:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levoxiracetam-nanjing-yoko-biomedical-cognitive-impairment-likelihood-of-approval/ 2024-03-19T01:52:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lutetium-miltuximab-glytherix-bladder-cancer-likelihood-of-approval/ 2024-05-20T05:23:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lutetium-miltuximab-glytherix-urethral-cancer-likelihood-of-approval/ 2024-05-20T05:23:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexicaserin-longboard-pharmaceuticals-dravet-syndrome-severe-myoclonic-epilepsy-of-infancy-likelihood-of-approval/ 2025-01-21T16:48:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046054-pfizer-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T18:18:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046054-pfizer-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-07-05T18:18:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046054-pfizer-melanoma-likelihood-of-approval/ 2024-07-05T18:18:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046054-pfizer-solid-tumor-likelihood-of-approval/ 2024-07-05T18:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046054-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T18:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmtx-101-clarametyx-biosciences-cystic-fibrosis-likelihood-of-approval/ 2025-01-21T16:47:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thiscart19a-suzhou-fundamenta-therapeutics-acquired-autoimmune-hemolytic-anemia-likelihood-of-approval/ 2025-01-21T16:48:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046054-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-07-05T18:18:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cs-12192-shenzhen-chipscreen-biosciences-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-06-19T15:56:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nitric-oxide-sanotize-research-and-development-oropharyngeal-candidiasis-likelihood-of-approval/ 2025-01-21T16:47:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prv-211-privo-technologies-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-02-20T18:40:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durcabtagene-autoleucel-novartis-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-02-20T18:40:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durcabtagene-autoleucel-novartis-refractory-multiple-myeloma-likelihood-of-approval/ 2024-02-20T18:40:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd123-for-relapsed-and-refractory-acute-myeloid-leukemia-chongqing-precision-biotech-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-02-20T18:39:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-03-shanghai-zhimeng-biopharma-epilepsy-likelihood-of-approval/ 2024-02-20T18:39:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prv-211-privo-technologies-lip-cancer-likelihood-of-approval/ 2024-02-20T18:39:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gdd-3898-lipidio-pharmaceuticals-dermatological-disorders-likelihood-of-approval/ 2024-09-09T05:51:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd123-for-relapsed-and-refractory-acute-myeloid-leukemia-chongqing-precision-biotech-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-02-20T18:39:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/df-1001-bristol-myers-squibb-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-09-09T05:50:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-905711-boehringer-ingelheim-international-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-07-05T18:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-801-arcus-biosciences-renal-cell-carcinoma-likelihood-of-approval/ 2024-02-20T18:36:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-801-arcus-biosciences-bladder-carcinoma-likelihood-of-approval/ 2024-02-20T18:36:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-801-arcus-biosciences-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-02-20T18:36:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-801-arcus-biosciences-breast-cancer-likelihood-of-approval/ 2024-02-20T18:35:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-801-arcus-biosciences-ovarian-cancer-likelihood-of-approval/ 2024-02-20T18:35:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-801-arcus-biosciences-colorectal-cancer-likelihood-of-approval/ 2024-02-20T18:35:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ociperlimab-beigene-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-09T05:50:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hb-admscs-hope-biosciences-primary-lateral-sclerosis-likelihood-of-approval/ 2025-01-21T16:47:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avc-101-avencell-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-09-09T05:50:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avc-101-avencell-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-09-09T05:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ociperlimab-beigene-solid-tumor-likelihood-of-approval/ 2024-09-09T05:50:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T16:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avc-101-avencell-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-09-09T05:50:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T16:47:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T16:47:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:50:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T16:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T16:47:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T16:47:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbx-12-cybrexa-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-21T16:47:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-3014-genmab-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-05-20T05:21:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-3014-genmab-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-05-20T05:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-3014-genmab-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-05-20T05:21:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-shanghai-henlius-biotech-giant-cell-tumor-of-bone-likelihood-of-approval/ 2025-01-21T16:47:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insulin-icodec-semaglutide-novo-nordisk-type-2-diabetes-likelihood-of-approval/ 2024-06-19T15:56:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/human-papillomavirus-serotypes-6-11-16-18-31-33-45-52-and-58-9-valent-vaccine-beijing-health-guard-biotechnology-human-papillomavirus-infections-likelihood-of-approval/ 2025-01-21T16:47:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-886-phanes-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:47:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-886-phanes-therapeutics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T16:47:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-886-phanes-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-21T16:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-199-phanes-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T16:47:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-199-phanes-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:47:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabotamig-arbele-gastric-cancer-likelihood-of-approval/ 2025-01-21T16:47:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/junctional-epidermolysis-bullosa-1-holostem-terapie-avanzate-epidermolysis-bullosa-likelihood-of-approval/ 2024-07-05T18:17:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/linperlisib-shanghai-yingli-pharmaceutical-t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-21T16:47:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ent-001-enthera-ulcerative-colitis-likelihood-of-approval/ 2024-02-20T18:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-21T16:46:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-bladder-cancer-likelihood-of-approval/ 2025-01-21T16:46:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-urethral-cancer-likelihood-of-approval/ 2025-01-21T16:46:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-ureter-cancer-likelihood-of-approval/ 2025-01-21T16:46:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rulonilimab-shandong-new-time-pharmaceutical-cervical-cancer-likelihood-of-approval/ 2025-01-21T16:46:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vis-954-visterra-transplant-rejection-likelihood-of-approval/ 2024-02-20T18:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vis-954-visterra-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2024-02-20T18:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tti-101-tvardi-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T16:46:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T16:46:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ds-3939-glycotope-solid-tumor-likelihood-of-approval/ 2024-07-05T18:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-07-05T18:16:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T18:16:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/irinotecan-hydrochloride-cspc-pharmaceutical-group-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T16:46:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-esophageal-cancer-likelihood-of-approval/ 2024-07-05T18:16:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-nasopharyngeal-cancer-likelihood-of-approval/ 2024-07-05T18:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-05T18:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-solid-tumor-likelihood-of-approval/ 2024-07-05T18:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-cervical-cancer-likelihood-of-approval/ 2024-07-05T18:16:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-07-05T18:16:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gfh-018-genfleet-therapeutics-shanghai-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-07-05T18:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/st316-sapience-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-21T16:46:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-dedifferentiated-liposarcoma-likelihood-of-approval/ 2025-01-21T16:46:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/certepetide-lisata-therapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T16:46:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tulmimetostat-morphosys-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-21T16:46:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tulmimetostat-morphosys-peritoneal-cancer-likelihood-of-approval/ 2025-01-21T16:46:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remibrutinib-novartis-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2025-01-21T16:46:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remibrutinib-novartis-relapsing-multiple-sclerosis-rms-likelihood-of-approval/ 2025-01-21T16:46:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-901-biomed-industries-major-depressive-disorder-likelihood-of-approval/ 2024-05-20T05:19:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986368-bristol-myers-squibb-epilepsy-likelihood-of-approval/ 2025-01-21T16:46:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/max-001-maxona-pharmaceuticals-pain-likelihood-of-approval/ 2024-02-20T18:07:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/remibrutinib-novartis-peanut-allergy-likelihood-of-approval/ 2025-01-21T16:46:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T16:46:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T16:45:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2025-01-21T16:45:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T16:46:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-gallbladder-cancer-likelihood-of-approval/ 2025-01-21T16:45:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-rectal-cancer-likelihood-of-approval/ 2025-01-21T16:45:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-esophageal-cancer-likelihood-of-approval/ 2025-01-21T16:45:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edv-2209-edvince-subarachnoid-hemorrhage-likelihood-of-approval/ 2025-01-21T16:45:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T16:45:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T16:45:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shylicine-hunazine-biotech-diarrhea-likelihood-of-approval/ 2024-02-20T18:03:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-544-selection-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-21T16:45:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mt-2990-mitsubishi-tanabe-pharma-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-anca-vasculitis-likelihood-of-approval/ 2025-01-21T16:45:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vesleteplirsen-sarepta-therapeutics-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-05-20T05:18:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/si-544-selection-psoriatic-arthritis-likelihood-of-approval/ 2025-01-21T16:45:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dsp-1083-sumitomo-pharma-parkinson-s-disease-likelihood-of-approval/ 2024-09-09T05:49:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glofitamab-f-hoffmann-la-roche-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:45:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adebrelimab-jiangsu-hengrui-medicine-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T16:45:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T16:45:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crx-100-bioeclipse-therapeutics-melanoma-likelihood-of-approval/ 2024-09-09T05:49:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crx-100-bioeclipse-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:49:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-sarcomas-likelihood-of-approval/ 2025-01-21T16:45:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-endometrial-cancer-likelihood-of-approval/ 2025-01-21T16:45:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T16:45:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T16:44:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-melanoma-likelihood-of-approval/ 2025-01-21T16:44:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifinatamab-deruxtecan-daiichi-sankyo-bladder-cancer-likelihood-of-approval/ 2025-01-21T16:45:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-gynecological-cancer-likelihood-of-approval/ 2025-01-21T16:44:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T16:44:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adagrasib-bristol-myers-squibb-uterine-cancer-likelihood-of-approval/ 2025-01-21T16:44:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-hepatocellular-carcinoma-likelihood-of-approval/ 2024-09-09T05:49:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T05:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/icg-136-icell-gene-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-02-20T17:53:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pivekimab-sunirine-immunogen-myeloproliferative-disorders-likelihood-of-approval/ 2025-01-21T16:44:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bo-112-highlight-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-09T05:49:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T16:44:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T16:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pivekimab-sunirine-immunogen-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T16:44:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-neuroblastoma-likelihood-of-approval/ 2025-01-21T16:44:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-esophageal-cancer-likelihood-of-approval/ 2025-01-21T16:44:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-metastatic-prostate-cancer-likelihood-of-approval/ 2025-01-21T16:44:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-head-and-neck-cancer-likelihood-of-approval/ 2025-01-21T16:44:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-gastrointestinal-stromal-tumor-gist-likelihood-of-approval/ 2025-01-21T16:44:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T16:44:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zerlasiran-silence-therapeutics-atherosclerosis-likelihood-of-approval/ 2025-01-21T16:44:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-lung-cancer-likelihood-of-approval/ 2025-01-21T16:44:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-603-advanced-accelerator-applications-ovarian-cancer-likelihood-of-approval/ 2025-01-21T16:44:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-1140-celldex-therapeutics-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T05:48:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/milvexian-bristol-myers-squibb-atrial-flutter-likelihood-of-approval/ 2025-01-21T16:44:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spesolimab-boehringer-ingelheim-international-pyoderma-gangrenosum-likelihood-of-approval/ 2025-01-21T16:44:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camrelizumab-jiangsu-hengrui-medicine-rectal-cancer-likelihood-of-approval/ 2025-01-21T16:43:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-paget-disease-of-bone-likelihood-of-approval/ 2025-01-21T16:43:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellular-immunotherapy-to-inhibit-pd-l1-for-oncology-immunitybio-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T16:43:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:15:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tirzepatide-eli-lilly-and-co-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-21T16:43:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nipocalimab-johnson-johnson-myasthenia-gravis-likelihood-of-approval/ 2025-01-21T16:43:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nipocalimab-johnson-johnson-primary-sjogren-s-syndrome-likelihood-of-approval/ 2025-01-21T16:43:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sintilimab-innovent-biologics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T16:43:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tadekinig-alfa-ab2-bio-hemophagocytic-lymphohistiocytosis-likelihood-of-approval/ 2024-05-20T05:15:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tadekinig-alfa-ab2-bio-lymphoproliferative-disorders-likelihood-of-approval/ 2024-05-20T05:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apo-2-aposcience-diabetic-foot-ulcers-likelihood-of-approval/ 2024-09-09T05:47:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexamethasone-sodium-phosphate-scilex-holding-back-pain-likelihood-of-approval/ 2024-02-20T17:31:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabatolimab-novartis-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-02-20T17:30:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:43:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ion-464-ionis-pharmaceuticals-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2025-01-21T16:43:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabatolimab-novartis-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-02-20T17:30:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabatolimab-novartis-gliosarcoma-likelihood-of-approval/ 2024-02-20T17:30:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jez-567-novartis-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:43:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jez-567-novartis-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:43:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cm-101-chemomab-therapeutics-liver-fibrosis-likelihood-of-approval/ 2024-07-05T18:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-21T16:43:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobolimab-gsk-cervical-cancer-likelihood-of-approval/ 2025-01-21T16:43:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-burkitt-lymphoma-likelihood-of-approval/ 2025-01-21T16:43:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T16:43:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:43:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T16:42:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T16:42:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anvatabart-opadotin-ambrx-biopharma-esophageal-cancer-likelihood-of-approval/ 2024-07-05T18:14:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-7000-biohaven-generalized-seizures-likelihood-of-approval/ 2025-01-21T16:42:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anvatabart-opadotin-ambrx-biopharma-metastatic-breast-cancer-likelihood-of-approval/ 2024-07-05T18:14:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T05:47:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-soft-tissue-sarcoma-likelihood-of-approval/ 2024-09-09T05:47:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-09-09T05:47:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fluticasone-propionate-eupraxia-pharmaceuticals-osteoarthritis-pain-likelihood-of-approval/ 2025-01-21T16:42:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-chondrosarcoma-likelihood-of-approval/ 2024-09-09T05:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cal-101-calluna-pharma-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2025-01-21T16:42:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pbf-999-palo-biofarma-prader-willi-syndrome-pws-likelihood-of-approval/ 2025-01-21T16:42:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cal-101-calluna-pharma-inflammation-likelihood-of-approval/ 2025-01-21T16:42:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cal-101-calluna-pharma-fibrosis-likelihood-of-approval/ 2025-01-21T16:42:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrabetadex-beren-therapeutics-pbc-atherosclerosis-likelihood-of-approval/ 2024-02-20T17:18:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tanimilast-chiesi-farmaceutici-asthma-likelihood-of-approval/ 2025-01-21T16:42:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lanifibranor-inventiva-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2024-06-19T06:20:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nms-153-nerviano-medical-sciences-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T16:42:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denifanstat-sagimet-biosciences-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-21T16:42:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msds-keytruda-sprints-towards-label-expansion-in-endometrial-cancer/ 2024-02-20T17:17:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-01-circio-holding-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:47:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tg-01-circio-holding-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-09-09T05:47:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/itacitinib-adipate-incyte-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-21T16:42:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/motixafortide-acetate-biolinerx-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T16:42:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enasidenib-mesylate-bristol-myers-squibb-cytopenia-likelihood-of-approval/ 2025-01-21T16:42:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coagulation-factor-ii-human-coagulation-factor-vii-human-coagulation-factor-ix-human-coagulation-factor-x-human-protein-c-human-takeda-pharmaceutical-blood-coagulation-likelihood-of-approval/ 2024-07-05T18:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-vulvar-cancer-likelihood-of-approval/ 2025-01-21T16:41:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T16:42:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-321-biontech-solid-tumor-likelihood-of-approval/ 2025-01-21T16:41:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-rectal-cancer-likelihood-of-approval/ 2025-01-21T16:41:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gildeuretinol-acetate-alkeus-pharmaceuticals-geographic-atrophy-likelihood-of-approval/ 2025-01-21T16:41:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-myxoid-liposarcoma-likelihood-of-approval/ 2025-01-21T16:41:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tonmya-tonix-pharmaceuticals-holding-fibromyalgia-fibromyalgia-syndrome-likelihood-of-approval/ 2024-06-19T06:20:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-angiosarcoma-of-scalp-likelihood-of-approval/ 2025-01-21T16:41:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-follicular-thyroid-cancer-likelihood-of-approval/ 2025-01-21T16:41:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-papillary-thyroid-cancer-likelihood-of-approval/ 2025-01-21T16:41:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-chordoma-likelihood-of-approval/ 2025-01-21T16:41:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-dysgerminoma-likelihood-of-approval/ 2025-01-21T16:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-primary-cns-lymphoma-likelihood-of-approval/ 2025-01-21T16:41:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-medullary-thyroid-cancer-likelihood-of-approval/ 2025-01-21T16:41:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T16:41:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T16:41:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-natural-killer-cell-lymphomas-likelihood-of-approval/ 2025-01-21T16:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2025-01-21T16:40:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-21T16:41:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-thymic-carcinoma-likelihood-of-approval/ 2025-01-21T16:40:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-melanoma-likelihood-of-approval/ 2025-01-21T16:40:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/duvelisib-secura-bio-t-cell-lymphomas-likelihood-of-approval/ 2025-01-21T16:40:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tebentafusp-immunocore-uveal-melanoma-likelihood-of-approval/ 2025-01-21T16:40:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-keloids-likelihood-of-approval/ 2025-01-21T16:40:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-alopecia-areata-likelihood-of-approval/ 2025-01-21T16:40:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-f-hoffmann-la-roche-colorectal-cancer-likelihood-of-approval/ 2025-01-21T16:40:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biogen-hairy-cell-leukemia-likelihood-of-approval/ 2025-01-21T16:40:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gevokizumab-novartis-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-02-20T17:03:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tamibarotene-syros-pharmaceuticals-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:40:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-neuroendocrine-carcinoma-likelihood-of-approval/ 2025-01-21T16:40:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tamibarotene-syros-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T16:40:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/felzartamab-human-immunology-biosciences-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2025-01-21T16:40:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/berubicin-hydrochloride-cns-pharmaceuticals-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T16:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adakitug-bristol-myers-squibb-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2025-01-21T16:40:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g-207-treovir-primitive-neuroectodermal-tumor-pnet-likelihood-of-approval/ 2025-01-21T16:39:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g-207-treovir-supratentorial-glioma-likelihood-of-approval/ 2025-01-21T16:39:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g-207-treovir-atypical-teratoid-rhabdoid-tumor-likelihood-of-approval/ 2025-01-21T16:39:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g-207-treovir-germ-cell-tumors-likelihood-of-approval/ 2025-01-21T16:39:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g-207-treovir-ependymoma-likelihood-of-approval/ 2025-01-21T16:39:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lumateperone-tosylate-intra-cellular-therapies-schizoaffective-disorder-likelihood-of-approval/ 2025-01-21T02:19:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vidutolimod-regeneron-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T02:19:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/catequentinib-hydrochloride-advenchen-laboratories-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T02:19:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ropeginterferon-alfa-2b-la-pharmaessentia-myelofibrosis-likelihood-of-approval/ 2025-01-21T02:19:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T02:19:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2025-01-21T02:19:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tagraxofusp-stemline-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T02:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bedaquiline-fumarate-johnson-johnson-leprosy-likelihood-of-approval/ 2024-09-09T05:45:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mogamulizumab-kyowa-kirin-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-05-20T05:09:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T02:19:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-metastatic-uveal-melanoma-likelihood-of-approval/ 2025-01-21T02:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mepolizumab-gsk-chronic-obstructive-pulmonary-disease-copd-likelihood-of-approval/ 2025-01-21T02:19:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgd-024-macrogenics-hairy-cell-leukemia-likelihood-of-approval/ 2025-01-21T02:18:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belimumab-gsk-cryoglobulinemia-likelihood-of-approval/ 2025-01-21T02:19:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/et-02-edigene-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T05:45:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mgd-024-macrogenics-systemic-mastocytosis-likelihood-of-approval/ 2025-01-21T02:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:45:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-09-09T05:45:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T05:45:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-hepatocellular-carcinoma-likelihood-of-approval/ 2024-09-09T05:44:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-solid-tumor-likelihood-of-approval/ 2024-09-09T05:44:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-09-09T05:45:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-head-and-neck-cancer-likelihood-of-approval/ 2024-09-09T05:44:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-gastric-cancer-likelihood-of-approval/ 2024-09-09T05:44:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-bladder-cancer-likelihood-of-approval/ 2024-09-09T05:44:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlx-66-telix-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T02:18:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlx-66-telix-pharmaceuticals-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T02:18:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlx-66-telix-pharmaceuticals-juvenile-myelomonocytic-leukemia-jmml-likelihood-of-approval/ 2025-01-21T02:18:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T05:44:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-melanoma-likelihood-of-approval/ 2024-09-09T05:44:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xolair-amplifies-reach-after-fda-approval-for-treating-food-allergies/ 2024-02-20T15:46:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ultimovacs-bags-ema-orphan-drug-status-for-cancer-vaccine/ 2024-02-20T14:29:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/benzalkonium-chloride-how-to-overcome-analytical-challenges/ 2024-02-20T14:27:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/key-mistakes-in-decentralised-clinical-trials-and-how-to-correct-them/ 2024-02-20T15:22:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-review-argenx-hytrulo-cidp/ 2024-02-20T11:03:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/singapore-affamed-ocular-treatment/ 2024-02-20T10:43:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-icosavax-acquisition/ 2024-02-20T09:18:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-velsipity-ec-approval/ 2024-02-20T09:14:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rpa-601-rocket-pharmaceuticals-net-present-value/ 2024-07-02T02:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volenrelaxin-eli-lilly-and-co-net-present-value/ 2024-07-02T02:12:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgx-202-regenxbio-net-present-value/ 2024-05-16T01:56:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvl-655-nuvalent-net-present-value/ 2024-05-16T02:10:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retatrutide-eli-lilly-and-co-net-present-value/ 2024-07-02T02:12:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dc-806-eli-lilly-and-co-net-present-value/ 2024-06-13T18:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-net-present-value/ 2024-06-13T18:55:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orforglipron-calcium-eli-lilly-and-co-net-present-value/ 2024-04-16T17:05:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ide-161-ideaya-biosciences-net-present-value/ 2024-05-16T02:10:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/renizgamglogene-autogedtemcel-editas-medicine-net-present-value/ 2024-05-16T02:10:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelicapavir-enanta-pharmaceuticals-net-present-value/ 2024-07-02T02:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empasiprubart-argenx-net-present-value/ 2024-07-02T02:04:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reolysin-oncolytics-biotech-net-present-value/ 2024-07-02T02:12:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bimagrumab-eli-lilly-and-co-net-present-value/ 2024-12-13T02:53:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-signs-antibody-deal-with-biocytogen-amid-adc-buzz/ 2024-02-19T15:07:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/daiichi-sankyo-and-astrazenecas-lung-cancer-antibody-set-for-fda-review/ 2024-02-19T14:03:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/applied-aims-for-approval-post-phase-iii-win-with-sord-deficiency-drug/ 2024-02-19T13:59:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/yet-another-clinical-hold-for-gileads-magrolimab-trials-2/ 2024-02-19T11:32:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/almirall-licences-il21-antibody-novo-nordisk/ 2024-02-19T11:02:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/celltrion-remsima-sc-ibd-canada/ 2024-02-19T11:00:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/iovance-amtagvi-melanoma-fda/ 2024-02-19T09:12:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-astrazeneca-tagrisso-nsclc/ 2024-02-19T09:12:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sareptas-elevidys-makes-advances-towards-expanded-dmd-label/ 2024-02-16T16:51:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/otsuka-wins-fda-breakthrough-therapy-designation-for-igan-drug/ 2024-02-16T16:48:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/qbiotics-wins-fda-orphan-status-for-rainforest-derived-cancer-drug/ 2024-02-16T16:11:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/regeneron-and-sanofis-dupixent-bags-fifth-drug-label-in-japan/ 2024-02-16T15:59:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dragonfly-gilead-cancer-therapy/ 2024-02-16T10:56:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-ionis-olezarsen-fcs/ 2024-02-16T11:01:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/xyphos-kelonia-drug-development/ 2024-02-16T08:19:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-aiolos-bio-acquisition/ 2024-02-16T09:02:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/psychedelic-treatments-for-mental-health-is-there-substance-behind-the-hype/ 2024-02-16T11:11:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/china-us-tensions-are-spilling-into-the-biotech-sector/ 2024-02-15T20:06:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-steps-closer-to-expanding-augtyros-use-for-treating-ntrk-solid-tumours/ 2024-02-15T19:24:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-maps-out-process-for-sponsors-to-charge-for-drugs-in-clinical-trials/ 2024-02-15T17:30:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-fast-tracks-diamyds-immunotherapy-for-managing-type-1-diabetes/ 2024-02-15T16:54:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mithra-sells-position-in-mayne-pharma-to-free-up-cash/ 2024-02-15T16:12:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/japan-fy-2024-pricing-reform-expected-to-favour-new-listed-innovative-drugs/ 2024-02-15T12:30:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ono-numab-antibody-cancer/ 2024-02-15T10:26:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/biotechs-ride-obesity-drug-wave-with-novel-approaches-that-go-beyond-glp-1ras/ 2024-09-16T13:00:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/latigo-pain-drug-development/ 2024-02-15T10:42:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-licence-elsie-oligonucleotide-platform/ 2024-02-15T08:53:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-eicos-aurlumyn-frostbite/ 2024-02-15T08:55:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-lawmakers-urge-administration-to-take-action-against-wuxi/ 2024-02-14T21:02:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/inclusivity-clinical-trials-scope-panel/ 2024-02-14T20:13:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-cracks-down-on-online-retailers-selling-unapproved-glp-1-agonists/ 2024-02-14T17:47:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-signs-674m-genai-drug-discovery-deal-with-vantai/ 2024-02-14T16:14:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/grifols-gears-up-for-fda-approval-of-fibrinogen-replacement-therapy/ 2024-02-14T15:08:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sudo-secures-additional-funds/ 2024-02-14T10:29:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-fast-track-status-edgewise/ 2024-02-14T10:24:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bioage-170m-obesity-therapeutics/ 2024-02-14T08:29:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ipsen-onivyde-fda-approval/ 2024-02-14T09:35:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/scope-fda-fireside-chat-ai-drug-development/ 2024-02-13T21:47:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/uk-agency-targets-blood-thinners-in-personalised-medicine-pursuit/ 2024-02-13T17:17:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gilead-aims-to-cash-in-on-liver-disease-wave-with-4-6bn-cymabay-deal/ 2024-02-13T17:01:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biovaxys-snatches-up-bankrupt-imvs-preclinical-and-clinical-assets/ 2024-02-13T15:52:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/crispr-gene-therapy-casgevy-secures-approval-in-europe/ 2024-02-13T15:37:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-concludes-acquisition-immunogen/ 2024-02-13T10:59:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/why-patient-centricity-is-the-answer-to-the-clinical-trial-enrolment-gap/ 2024-02-13T17:03:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-saama-expand-deal/ 2024-02-13T10:59:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-fast-track-gsk-bepirovirsen/ 2024-02-13T09:37:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/takeda-eohilia-fda-approval/ 2024-02-13T09:36:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/the-opioid-crisis-different-delivery-systems-tackle-treatment-needs/ 2024-02-12T21:29:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-immuno-oncology-pharmaceutical-industry/ 2024-12-02T16:37:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-energy-transition-pharmaceutical-industry/ 2024-09-10T02:24:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-cloud-pharmaceutical-industry/ 2024-12-02T16:38:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-renewable-energy-pharmaceutical-industry/ 2024-02-13T07:45:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-easy-affordable-pharmaceutical-industry/ 2024-02-13T07:46:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-remote-patient-monitoring-pharmaceutical-industry/ 2024-02-13T07:46:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-electronic-medical-record-emr-systems-pharmaceutical-industry/ 2024-02-13T07:46:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-mobile-health-pharmaceutical-industry/ 2024-12-02T16:38:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-cybersecurity-pharmaceutical-industry/ 2024-02-13T07:46:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-microbiome-pharmaceutical-industry/ 2024-05-21T02:28:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-environmental-sustainability-pharmaceutical-industry/ 2024-12-02T16:38:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/dashboards/deals-dashboards/ma-activity-health-wellness-pharmaceutical-industry/ 2024-12-02T16:38:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/science-and-menopause-under-the-spotlight-during-the-super-bowl/ 2024-02-12T16:44:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/disc-wins-orphan-drug-tag-for-rare-blood-cancer/ 2024-02-12T16:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/first-targeted-alpha-therapy-wins-fda-breakthrough-device-designation/ 2024-02-12T15:17:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/csls-big-post-heart-attack-drug-fails-in-phase-iii-trial/ 2024-02-12T14:36:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alys-pharmaceuticals-announces-launch/ 2024-02-12T10:52:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-licence-pfizer-biontech-vaccine/ 2024-02-12T10:19:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/innovate-uk-funds-breast-cancer/ 2024-02-12T08:25:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-breakthrough-jj-nipocalimab/ 2024-02-12T09:21:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/hemogenyx-gets-reprieve-as-fda-lifts-clinical-hold-on-aml-car-t-therapy/ 2024-02-14T10:30:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-senate-committee-interrogates-big-pharma-on-outrageously-high-drug-prices/ 2024-02-09T15:54:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/vicore-licenses-idiopathic-pulmonary-fibrosis-therapy-to-nippon-in-japan/ 2024-02-09T15:44:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/another-recall-does-philips-have-a-quality-control-problem/ 2024-02-09T15:19:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/novo-to-buy-catalent-the-backlash-begins/ 2024-11-22T11:01:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/janssen-ema-rybrevant-nsclc/ 2024-02-09T10:50:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-cbmed-cancer-therapies/ 2024-02-09T10:51:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-fy-2023-profit-after-tax/ 2024-02-09T09:28:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biontech-autolus-car-t-therapies/ 2024-02-14T10:30:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/undisclosed-1-palleon-pharmaceuticals-autoimmune-disorders-likelihood-of-approval/ 2024-09-09T05:44:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nikogene-kian-immune-cell-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2025-01-21T02:18:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opl-053-overseas-pharmaceuticals-insomnia-likelihood-of-approval/ 2024-02-09T05:16:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opl-044-overseas-pharmaceuticals-epilepsy-likelihood-of-approval/ 2024-02-09T05:15:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/candi-5v-limmatech-biologics-vulvovaginal-candidiasis-likelihood-of-approval/ 2024-02-09T05:15:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-161734-incyte-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T02:18:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-161734-incyte-solid-tumor-likelihood-of-approval/ 2025-01-21T02:18:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-161734-incyte-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07985819-pfizer-pandemic-influenza-likelihood-of-approval/ 2024-02-09T05:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/smp-190-xiling-lab-solid-tumor-likelihood-of-approval/ 2025-01-21T02:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-8421-astrazeneca-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T02:18:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-8421-astrazeneca-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-21T02:18:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986453-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-04-20T01:48:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986453-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-04-20T01:48:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3938577-eli-lilly-and-co-type-2-diabetes-likelihood-of-approval/ 2024-07-05T18:10:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3971297-eli-lilly-and-co-obesity-likelihood-of-approval/ 2025-01-21T02:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ly-3971297-eli-lilly-and-co-hypertension-likelihood-of-approval/ 2025-01-21T02:18:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kyn-5356-kynexis-therapeutics-cognitive-impairment-associated-with-schizophrenia-cias-likelihood-of-approval/ 2025-01-21T02:18:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rem-422-remix-therapeutics-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2024-06-19T06:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-universal-car-gamma-delta-t-guangzhou-bio-gene-technology-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-02-09T05:10:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vgb-ex01-shanghai-vitalgen-biopharma-beta-thalassaemia-likelihood-of-approval/ 2024-02-09T05:09:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdk4-inhibitor-beigene-breast-cancer-likelihood-of-approval/ 2024-02-09T05:09:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-6422-astrazeneca-gastrointestinal-tumor-likelihood-of-approval/ 2025-01-21T02:18:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-24c5-lanova-medicines-solid-tumor-likelihood-of-approval/ 2025-01-21T02:18:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/invariant-natural-killer-t-cells-beijing-gene-key-life-technology-hepatocellular-carcinoma-likelihood-of-approval/ 2024-02-09T05:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/skg-0106-skyline-therapeutics-shanghai-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-07-05T18:10:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ino-6160-inovio-pharmaceuticals-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-21T02:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hnc-1058-guangzhou-henovcom-bioscience-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-02-09T05:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hnc-1058-guangzhou-henovcom-bioscience-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-02-09T05:06:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lcar-g08-legend-biotech-pancreatic-cancer-likelihood-of-approval/ 2024-04-20T01:48:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jwk-008-chengdu-genevector-biotechnology-mucopolysaccharidosis-i-mps-i-hurler-syndrome-likelihood-of-approval/ 2024-02-09T05:05:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ker-065-keros-therapeutics-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-05-20T05:08:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ker-065-keros-therapeutics-obesity-likelihood-of-approval/ 2024-05-20T05:08:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-0201-gilead-sciences-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T02:18:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-0201-gilead-sciences-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T02:17:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-0201-gilead-sciences-solid-tumor-likelihood-of-approval/ 2025-01-21T02:17:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-825-fate-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-20T01:48:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-79635322-johnson-johnson-primary-systemic-amyloidosis-likelihood-of-approval/ 2025-01-21T02:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empagliflozin-metformin-sitagliptin-chong-kun-dang-pharmaceutical-type-2-diabetes-likelihood-of-approval/ 2024-02-09T05:02:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afnt-111-affini-t-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-02-09T05:02:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afnt-111-affini-t-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-02-09T05:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afnt-111-affini-t-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-02-09T05:01:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rbs-2418-riboscience-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T02:17:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-1614-gilead-sciences-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-21T02:17:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inf-904-inflarx-chronic-inflammation-likelihood-of-approval/ 2025-01-21T02:17:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inf-904-inflarx-autoimmune-disorders-likelihood-of-approval/ 2025-01-21T02:17:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/favezelimab-pembrolizumab-merck-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-21T02:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mm-402-mind-medicine-mindmed-autism-spectrum-disorder-asd-likelihood-of-approval/ 2024-02-09T04:59:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agomelatine-alto-neuroscience-major-depressive-disorder-likelihood-of-approval/ 2024-02-22T01:35:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alto-203-alto-neuroscience-major-depressive-disorder-likelihood-of-approval/ 2024-05-20T05:08:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-curateq-biologics-allergic-asthma-likelihood-of-approval/ 2025-01-21T02:17:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-curateq-biologics-nasal-polyps-nasal-polyposis-likelihood-of-approval/ 2025-01-21T02:17:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-418-1st-bio-therapeutics-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-02-09T04:57:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-418-1st-bio-therapeutics-parkinson-s-disease-likelihood-of-approval/ 2024-02-09T04:56:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-2102-novartis-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-06-19T06:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sg-2501-hangzhou-sumgen-biotech-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-21T02:17:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sg-2501-hangzhou-sumgen-biotech-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-21T02:17:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipg-1094-immunophage-biotech-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2025-01-21T02:17:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipg-1094-immunophage-biotech-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-21T02:17:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipg-1094-immunophage-biotech-psoriasis-likelihood-of-approval/ 2025-01-21T02:17:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipg-1094-immunophage-biotech-multiple-sclerosis-likelihood-of-approval/ 2025-01-21T02:17:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-zhuhai-beihai-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T02:17:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-zhuhai-beihai-biotech-gastric-cancer-likelihood-of-approval/ 2025-01-21T02:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-zhuhai-beihai-biotech-prostate-cancer-likelihood-of-approval/ 2025-01-21T02:16:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-zhuhai-beihai-biotech-breast-cancer-likelihood-of-approval/ 2025-01-21T02:16:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ngn-401-neurogene-rett-syndrome-likelihood-of-approval/ 2025-01-21T02:16:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/ 2024-09-09T05:43:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-09-09T05:43:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-103-shanghai-simnova-biotechnology-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-09-09T05:43:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vvd-130850-vividion-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T02:16:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vvd-130850-vividion-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T02:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vvd-130850-vividion-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T02:16:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cyb-004-cybin-social-anxiety-disorder-sad-social-phobia-likelihood-of-approval/ 2024-09-09T05:43:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ine-963-novartis-malaria-likelihood-of-approval/ 2024-02-09T04:44:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sns-101-sensei-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:09:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sns-101-sensei-biotherapeutics-head-and-neck-cancer-likelihood-of-approval/ 2024-07-05T18:09:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sns-101-sensei-biotherapeutics-melanoma-likelihood-of-approval/ 2024-07-05T18:09:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sns-101-sensei-biotherapeutics-colorectal-cancer-likelihood-of-approval/ 2024-07-05T18:09:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-012-caribou-biosciences-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T02:16:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-012-caribou-biosciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T02:16:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sng-100-seanergy-dermatology-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-02-09T04:41:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-1012-kalivir-immunotherapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-09-09T05:43:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-1012-kalivir-immunotherapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:43:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-1012-kalivir-immunotherapeutics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-09-09T05:43:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-1012-kalivir-immunotherapeutics-metastatic-melanoma-likelihood-of-approval/ 2024-09-09T05:43:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-1012-kalivir-immunotherapeutics-gastric-cancer-likelihood-of-approval/ 2024-09-09T05:43:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sibp-03-shanghai-institute-of-biological-products-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-02-09T04:39:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/srp-3d-south-rampart-pharma-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-04-20T01:46:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tofacitinib-biora-therapeutics-ulcerative-colitis-likelihood-of-approval/ 2024-02-09T04:39:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anb-10-biocad-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2024-02-09T04:38:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-101-tscan-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-09-09T05:43:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-101-tscan-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-09-09T05:43:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-101-tscan-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-09-09T05:43:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lorpucitinib-johnson-johnson-familial-adenomatous-polyposis-likelihood-of-approval/ 2024-07-05T18:09:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-5381-regeneron-pharmaceuticals-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2025-01-21T02:16:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hu-6-rivus-pharmaceuticals-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2025-01-21T02:16:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hu-6-rivus-pharmaceuticals-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2025-01-21T02:16:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hu-6-rivus-pharmaceuticals-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-21T02:16:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:16:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvcls-579-calico-life-sciences-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T02:16:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvcls-579-calico-life-sciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T02:16:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvcls-579-calico-life-sciences-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T02:16:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvcls-579-calico-life-sciences-solid-tumor-likelihood-of-approval/ 2025-01-21T02:16:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexicaserin-longboard-pharmaceuticals-tuberous-sclerosis-likelihood-of-approval/ 2025-01-21T02:16:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1910-bioinvent-international-solid-tumor-likelihood-of-approval/ 2024-04-20T01:45:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vent-03-ventus-therapeutics-neuroinflammation-likelihood-of-approval/ 2025-01-21T02:16:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vent-03-ventus-therapeutics-dermatomyositis-likelihood-of-approval/ 2025-01-21T02:15:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vent-03-ventus-therapeutics-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-21T02:15:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vent-03-ventus-therapeutics-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-21T02:15:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eos-984-iteos-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-20T01:45:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rct-1100-recode-therapeutics-primary-ciliary-dyskinesia-likelihood-of-approval/ 2025-01-21T02:15:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dsp-0390-sumitomo-pharma-oligodendroglioma-likelihood-of-approval/ 2025-01-21T02:15:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dsp-0390-sumitomo-pharma-anaplastic-astrocytoma-likelihood-of-approval/ 2025-01-21T02:15:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amtx-100-amytrx-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-09-09T05:43:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-thymic-carcinoma-likelihood-of-approval/ 2025-01-21T02:15:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-21T02:15:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-esophageal-cancer-likelihood-of-approval/ 2025-01-21T02:15:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2025-01-21T02:15:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T02:15:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-anal-cancer-likelihood-of-approval/ 2025-01-21T02:15:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-solid-tumor-likelihood-of-approval/ 2025-01-21T02:15:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T02:15:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-colon-cancer-likelihood-of-approval/ 2025-01-21T02:15:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-melanoma-likelihood-of-approval/ 2025-01-21T02:15:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-ovarian-cancer-likelihood-of-approval/ 2025-01-21T02:15:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-breast-cancer-likelihood-of-approval/ 2025-01-21T02:15:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sbt-777101-sonoma-biotherapeutics-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-21T02:15:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-3011-immvira-malignant-ascites-likelihood-of-approval/ 2025-01-21T02:15:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-3011-immvira-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:14:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T02:14:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bosakitug-biosion-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-21T02:14:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/celecoxib-ciprofloxacin-neurosense-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2024-09-09T05:43:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T02:14:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T02:14:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T02:14:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-21T02:14:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2025-01-21T02:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-sezary-syndrome-likelihood-of-approval/ 2025-01-21T02:14:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-t-cell-leukemia-likelihood-of-approval/ 2025-01-21T02:14:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-t-cell-lymphomas-likelihood-of-approval/ 2025-01-21T02:14:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adely-01-adel-alzheimer-s-disease-likelihood-of-approval/ 2025-01-21T02:14:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-100-tscan-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-02-09T04:16:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-100-tscan-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-02-09T04:16:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-100-tscan-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-02-09T04:15:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/garsorasib-inventisbio-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T02:14:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd30-wuhan-bio-raid-biotechnology-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-09-09T05:42:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd30-wuhan-bio-raid-biotechnology-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T05:42:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenalidomide-starton-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-02-09T04:13:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenalidomide-starton-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-02-09T04:13:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dx-126262-hangzhou-dac-biotech-urethral-cancer-likelihood-of-approval/ 2025-01-21T02:14:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemacabtagene-ansegedleucel-allogene-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T02:14:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemacabtagene-ansegedleucel-allogene-therapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T02:14:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brogidirsen-nippon-shinyaku-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-05-20T05:05:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/son-1010-sonnet-biotherapeutics-mesenchymal-tumor-likelihood-of-approval/ 2025-01-21T02:14:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dt-2216-dialectic-therapeutics-blood-cancer-likelihood-of-approval/ 2025-01-21T02:14:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dt-2216-dialectic-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T02:14:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-129-merus-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2025-01-21T02:14:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-129-merus-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T02:13:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-129-merus-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T02:13:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdtx-1535-black-diamond-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T06:14:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opl-015-overseas-pharmaceuticals-pain-likelihood-of-approval/ 2024-02-09T04:03:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T02:13:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T02:13:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T02:13:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T02:13:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zilovertamab-vedotin-merck-lymphoma-likelihood-of-approval/ 2025-01-21T02:13:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ruxoprubart-novelmed-therapeutics-paroxysmal-nocturnal-hemoglobinuria-likelihood-of-approval/ 2025-01-21T02:13:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pxs-5505a-syntara-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T02:13:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pxs-5505a-syntara-scar-likelihood-of-approval/ 2025-01-21T02:13:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sotorasib-amgen-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:13:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crv-101-curevo-herpes-zoster-shingles-likelihood-of-approval/ 2025-01-21T02:13:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T02:13:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-angiosarcoma-likelihood-of-approval/ 2025-01-21T02:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T02:13:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T02:13:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-endometrial-cancer-likelihood-of-approval/ 2025-01-21T02:12:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T02:12:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T02:12:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-cervical-cancer-likelihood-of-approval/ 2025-01-21T02:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/botensilimab-agenus-ovarian-cancer-likelihood-of-approval/ 2025-01-21T02:12:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-endometrial-cancer-likelihood-of-approval/ 2025-01-21T02:12:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muzastotug-adagene-suzhou-cervical-cancer-likelihood-of-approval/ 2025-01-21T02:12:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tulmimetostat-morphosys-mycosis-fungoides-likelihood-of-approval/ 2025-01-21T02:12:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tulmimetostat-morphosys-sezary-syndrome-likelihood-of-approval/ 2025-01-21T02:12:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-compass-pathways-anorexia-nervosa-likelihood-of-approval/ 2025-01-21T02:11:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aaa-817-novartis-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T02:11:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T02:11:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T02:11:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T02:11:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-peritoneal-cancer-likelihood-of-approval/ 2025-01-21T02:11:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-21T02:11:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T02:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:11:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2025-01-21T02:11:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T02:11:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T02:11:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T02:11:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T02:11:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T02:11:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-21T02:11:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-gallbladder-cancer-likelihood-of-approval/ 2025-01-21T02:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-gastric-cancer-likelihood-of-approval/ 2025-01-21T02:10:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-cervical-cancer-likelihood-of-approval/ 2025-01-21T02:10:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivonescimab-akeso-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:10:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T02:10:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-squamous-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2025-01-21T02:10:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T02:10:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T02:10:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:10:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sln-124-silence-therapeutics-alpha-thalassaemia-likelihood-of-approval/ 2025-01-21T02:10:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mufemilast-tianjin-hemay-pharmaceutical-ankylosing-spondylitis-bekhterev-s-disease-likelihood-of-approval/ 2024-05-20T05:01:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/datopotamab-deruxtecan-daiichi-sankyo-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T02:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venadaparib-idience-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-09-09T05:41:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ino-5401-inovio-pharmaceuticals-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-02-09T03:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lorundrostat-hydrobromide-mineralys-therapeutics-hypertension-likelihood-of-approval/ 2024-02-09T03:21:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-09-09T05:41:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T05:41:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-solid-tumor-likelihood-of-approval/ 2024-09-09T05:41:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-09-09T05:41:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-bladder-cancer-likelihood-of-approval/ 2024-09-09T05:41:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:41:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-09-09T05:41:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bt-1718-bicycle-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-09-09T05:41:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-4157-moderna-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T02:10:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-4157-moderna-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T02:10:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-4157-moderna-gastric-cancer-likelihood-of-approval/ 2025-01-21T02:10:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfp-14927-delta-fly-pharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T02:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0486-astrazeneca-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-21T02:10:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfp-14927-delta-fly-pharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T02:10:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fexuprazan-daewoong-helicobacter-pylori-infections-likelihood-of-approval/ 2025-01-21T02:10:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-edotreotide-itm-isotope-technologies-munich-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-21T02:10:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-colorectal-cancer-likelihood-of-approval/ 2025-01-21T02:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-21T02:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atrn-119-aprea-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T02:09:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T02:09:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-57643-incyte-myelofibrosis-likelihood-of-approval/ 2025-01-21T02:09:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edetate-disodium-ethyl-alcohol-minocycline-hydrochloride-citius-pharmaceuticals-staphylococcus-aureus-infections-likelihood-of-approval/ 2025-01-21T02:09:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edetate-disodium-ethyl-alcohol-minocycline-hydrochloride-citius-pharmaceuticals-pseudomonas-aeruginosa-infections-likelihood-of-approval/ 2025-01-21T02:09:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edetate-disodium-ethyl-alcohol-minocycline-hydrochloride-citius-pharmaceuticals-fungal-infections-likelihood-of-approval/ 2025-01-21T02:09:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapotoclax-amgen-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2025-01-21T02:09:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vorolanib-eyepoint-pharmaceuticals-diabetic-macular-edema-likelihood-of-approval/ 2025-01-21T02:09:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/verekitug-upstream-bio-rhinosinusitis-likelihood-of-approval/ 2025-01-21T02:09:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapotoclax-amgen-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T02:09:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T02:09:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/verekitug-upstream-bio-asthma-likelihood-of-approval/ 2025-01-21T02:09:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fpi-1434-fusion-pharmaceuticals-ewing-sarcoma-likelihood-of-approval/ 2025-01-21T02:09:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zelicapavir-enanta-pharmaceuticals-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-07-05T18:03:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belrestotug-gsk-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T02:09:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-uveal-melanoma-likelihood-of-approval/ 2025-01-21T02:09:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-21T02:09:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luvixasertib-treadwell-therapeutics-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T02:09:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luvixasertib-treadwell-therapeutics-sarcomas-likelihood-of-approval/ 2025-01-21T02:09:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luvixasertib-treadwell-therapeutics-endometrial-cancer-likelihood-of-approval/ 2025-01-21T02:09:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luvixasertib-treadwell-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T01:40:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luvixasertib-treadwell-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T02:08:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luvixasertib-treadwell-therapeutics-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-gd2-for-oncology-bristol-myers-squibb-neuroblastoma-likelihood-of-approval/ 2025-01-21T01:40:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vxag-1-1nn-vaxart-norovirus-infections-likelihood-of-approval/ 2024-02-09T03:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alxn-2220-alexion-pharmaceuticals-amyloid-cardiomyopathy-likelihood-of-approval/ 2024-06-19T06:11:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbm-c30-1-abelzeta-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T05:40:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vonafexor-enyo-pharma-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-07-05T18:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ser-155-seres-therapeutics-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-21T01:40:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isuzinaxib-aptabio-therapeutics-acute-renal-failure-arf-acute-kidney-injury-likelihood-of-approval/ 2025-01-21T01:40:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maplirpacept-pfizer-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:40:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rusfertide-acetate-protagonist-therapeutics-polycythemia-vera-likelihood-of-approval/ 2025-01-21T01:40:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vactosertib-medpacto-osteosarcoma-likelihood-of-approval/ 2025-01-21T01:40:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/balstilimab-agenus-solid-tumor-likelihood-of-approval/ 2025-01-21T01:40:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inclisiran-novartis-homozygous-familial-hypercholesterolemia-hofh-likelihood-of-approval/ 2025-01-21T01:40:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-cervical-cancer-likelihood-of-approval/ 2024-05-20T04:59:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zalifrelimab-agenus-solid-tumor-likelihood-of-approval/ 2024-05-20T04:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T01:40:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-0123-debiopharm-international-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:40:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-sezary-syndrome-likelihood-of-approval/ 2025-01-21T01:40:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-0123-debiopharm-international-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-21T01:39:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-0123-debiopharm-international-peritoneal-cancer-likelihood-of-approval/ 2025-01-21T01:40:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gc-1118a-gc-biopharma-gastric-cancer-likelihood-of-approval/ 2025-01-21T01:39:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-0123-debiopharm-international-uterine-cancer-likelihood-of-approval/ 2025-01-21T01:39:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitapivat-sulfate-agios-pharmaceuticals-alpha-thalassaemia-likelihood-of-approval/ 2024-05-20T04:59:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empasiprubart-argenx-delayed-graft-function-dgf-likelihood-of-approval/ 2025-01-21T01:39:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-2100-biohaven-migraine-likelihood-of-approval/ 2025-01-21T01:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexanolone-sage-therapeutics-alcohol-dependence-likelihood-of-approval/ 2024-02-08T20:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anvatabart-opadotin-ambrx-biopharma-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T18:03:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prabotulinumtoxin-a-biosimilar-aeon-biopharma-spasmodic-torticollis-cervical-dystonia-likelihood-of-approval/ 2024-09-09T05:40:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexanolone-sage-therapeutics-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/ 2024-02-08T20:24:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemdisiran-alnylam-pharmaceuticals-myasthenia-gravis-likelihood-of-approval/ 2025-01-21T01:39:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pruxelutamide-kintor-pharmaceutical-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2025-01-21T01:39:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-polymyositis-likelihood-of-approval/ 2025-01-21T01:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/motrem-inotrem-septic-shock-likelihood-of-approval/ 2024-02-08T20:20:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenocutuzumab-merus-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-21T01:39:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pxs-4728-syntara-parkinson-s-disease-likelihood-of-approval/ 2025-01-21T01:39:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levetiracetam-er-agenebio-psychosis-likelihood-of-approval/ 2024-02-08T20:19:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/testosterone-undecanoate-marius-pharmaceuticals-male-infertility-likelihood-of-approval/ 2025-01-21T01:39:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tu-2218-tiumbio-cervical-cancer-likelihood-of-approval/ 2024-06-19T06:10:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tu-2218-tiumbio-colorectal-cancer-likelihood-of-approval/ 2024-06-19T06:10:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ilixadencel-mendus-hepatocellular-carcinoma-likelihood-of-approval/ 2024-09-09T05:39:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ilixadencel-mendus-gastrointestinal-stromal-tumor-gist-likelihood-of-approval/ 2024-09-09T05:39:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crenigacestat-eli-lilly-and-co-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-09-09T05:39:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crenigacestat-eli-lilly-and-co-refractory-multiple-myeloma-likelihood-of-approval/ 2024-09-09T05:39:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denifanstat-sagimet-biosciences-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T01:39:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vericiguat-bayer-metabolic-syndrome-likelihood-of-approval/ 2025-01-21T01:39:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vericiguat-bayer-vascular-dysfunction-likelihood-of-approval/ 2025-01-21T01:39:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirexatamab-leap-therapeutics-esophageal-cancer-likelihood-of-approval/ 2025-01-21T01:38:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirexatamab-leap-therapeutics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T01:38:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirexatamab-leap-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-21T01:38:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirexatamab-leap-therapeutics-endometrial-cancer-likelihood-of-approval/ 2025-01-21T01:38:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-jazz-pharmaceuticals-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T01:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirexatamab-leap-therapeutics-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:38:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2025-01-21T01:38:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:38:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:38:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/letetresgene-autoleucel-adaptimmune-therapeutics-myxoid-liposarcoma-likelihood-of-approval/ 2024-09-09T05:39:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/letetresgene-autoleucel-adaptimmune-therapeutics-round-cell-liposarcoma-likelihood-of-approval/ 2024-09-09T05:39:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/letetresgene-autoleucel-adaptimmune-therapeutics-synovial-sarcoma-likelihood-of-approval/ 2024-09-09T05:39:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sepetaprost-santen-pharmaceutical-ocular-hypertension-likelihood-of-approval/ 2025-01-21T01:38:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sepetaprost-santen-pharmaceutical-open-angle-glaucoma-likelihood-of-approval/ 2025-01-21T01:38:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medi-0457-astrazeneca-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-21T01:38:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/albumin-human-grifols-ascites-likelihood-of-approval/ 2024-07-05T18:02:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-biosimilar-prestige-biopharma-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:38:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/progesterone-ibsa-institut-biochimique-female-infertility-likelihood-of-approval/ 2024-02-08T20:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gildeuretinol-acetate-alkeus-pharmaceuticals-juvenile-macular-degeneration-stargardt-disease-likelihood-of-approval/ 2025-01-21T01:37:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedeptin-geovax-labs-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:37:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avadomide-hydrochloride-bristol-myers-squibb-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T01:37:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:37:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-21T01:37:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-21T01:37:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-21T01:37:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-esophageal-cancer-likelihood-of-approval/ 2025-01-21T01:37:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-21T01:37:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T01:37:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-gastric-cancer-likelihood-of-approval/ 2025-01-21T01:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:37:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orismilast-union-therapeutics-ulcerative-colitis-likelihood-of-approval/ 2024-07-05T18:01:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orismilast-union-therapeutics-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-07-05T18:01:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orismilast-union-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-07-05T18:01:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-dotatate-advanced-accelerator-applications-pheochromocytoma-likelihood-of-approval/ 2025-01-21T01:37:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-f-hoffmann-la-roche-ductal-carcinoma-in-situ-likelihood-of-approval/ 2024-02-08T19:58:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/taladegib-endeavor-biomedicines-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-21T01:36:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/onvansertib-fumarate-cardiff-oncology-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T01:36:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anifrolumab-astrazeneca-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-21T01:36:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlx-250-telix-pharmaceuticals-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:36:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acimtamig-affimed-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-21T01:36:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/siltuximab-recordati-pain-likelihood-of-approval/ 2025-01-21T01:36:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vidutolimod-regeneron-pharmaceuticals-melanoma-likelihood-of-approval/ 2025-01-21T01:36:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tertomotide-gemvax-kael-breast-cancer-likelihood-of-approval/ 2025-01-21T01:36:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naxitamab-y-mabs-therapeutics-osteosarcoma-likelihood-of-approval/ 2025-01-21T01:36:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T01:36:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mycophenolate-mofetil-f-hoffmann-la-roche-lupus-nephritis-likelihood-of-approval/ 2025-01-21T01:36:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:36:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isatuximab-sanofi-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:36:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/docetaxel-plus-therapeutics-cervical-cancer-likelihood-of-approval/ 2024-05-20T04:55:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empagliflozin-boehringer-ingelheim-international-pulmonary-arterial-hypertension-likelihood-of-approval/ 2025-01-21T01:36:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-ureter-cancer-likelihood-of-approval/ 2025-01-21T01:35:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/valbenazine-tosylate-neurocrine-biosciences-trichotillomania-likelihood-of-approval/ 2025-01-21T01:35:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-bladder-cancer-likelihood-of-approval/ 2025-01-21T01:35:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-urethral-cancer-likelihood-of-approval/ 2025-01-21T01:35:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/varlilumab-celldex-therapeutics-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T05:38:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponatinib-hydrochloride-takeda-pharmaceutical-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:35:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T01:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:35:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/varlilumab-celldex-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T05:06:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-natural-killer-cell-lymphomas-likelihood-of-approval/ 2025-01-21T01:35:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2025-01-21T01:35:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T05:06:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T05:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-09T05:06:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T05:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-esophageal-cancer-likelihood-of-approval/ 2024-09-09T05:06:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-09-09T05:06:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-solid-tumor-likelihood-of-approval/ 2024-09-09T05:06:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-endometrial-cancer-likelihood-of-approval/ 2024-09-09T05:06:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-ovarian-cancer-likelihood-of-approval/ 2024-09-09T05:06:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T05:06:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-bladder-cancer-likelihood-of-approval/ 2024-09-09T05:06:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:35:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nx-5948-nurix-therapeutics-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:35:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalbavancin-abbvie-methicillin-resistant-staphylococcus-aureus-mrsa-infections-likelihood-of-approval/ 2025-01-21T01:35:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:34:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T01:35:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:35:06+00:00 daily 0.2